Get the Stockscreener App
91.84
0.21%
0.19
After Hours:
91.84
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $91.84, with a volume of 6.45M.
It is up +0.21% in the last 24 hours and down -1.03% over the past month.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$91.65
Open:
$92.01
24h Volume:
6.45M
Relative Volume:
1.06
Market Cap:
$114.43B
Revenue:
$28.30B
Net Income/Loss:
$126.00M
P/E Ratio:
1,020.44
EPS:
0.09
Net Cash Flow:
$9.43B
1W Performance:
+2.18%
1M Performance:
-1.03%
6M Performance:
+25.29%
1Y Performance:
+6.20%
1-Day Range:
$91.69
$92.80
1-Week Range:
$89.02
$93.07
52-Week Range:
$62.07
$98.90
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
91.84 | 114.43B | 28.30B | 126.00M | 9.43B | 0.09 |
|
LLY
Lilly Eli Co
|
725.72 | 689.73B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
78.69 | 349.44B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
147.03 | 344.63B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
171.56 | 303.17B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
97.92 | 251.88B | 63.17B | 12.15B | 14.84B | 4.77 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
Can Gilead Sciences Sustain Its Growth Momentum In 2025? - Barchart
Can Gilead Sciences Sustain Its Growth Momentum in 2025? - Yahoo Finance
Gilead’s Livdelzi approved by MHRA to treat primary biliary cholangitis in adults - PMLiVE
HB Wealth Management LLC Purchases 8,406 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Hennion & Walsh Asset Management Inc. - MarketBeat
Gilead Sciences Q2 EPS Estimate Boosted by Zacks Research - MarketBeat
Liberty One Investment Management LLC Sells 7,350 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Nexus Investment Management ULC Trims Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Premier Path Wealth Partners LLC Has $744,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Arkadios Wealth Advisors Reduces Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Boston Common Asset Management LLC Sells 53,301 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Wedge Capital Management L L P NC Sells 86,409 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Park Avenue Securities LLC Buys 6,878 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) CFO Sells $228,375.00 in Stock - MarketBeat
Advanced biologic developer Gilead cites manufacturing efficiencies as CAR-T advantage in 2025 - BioProcess Insider
Gilead Sciences CFO sells shares worth $228,375 - MSN
Earnings Preview: What to Expect From Gilead Sciences’ Report - Nasdaq
Earnings Preview: What To Expect From Gilead Sciences’ Report - Barchart
Occidental Asset Management LLC Acquires 3,980 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Stock Position Trimmed by Sicart Associates LLC - MarketBeat
Gateway Investment Advisers LLC Trims Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Global Pharma & Biotech CRM Software Market To Surpass Valuation of US$ 20.0 Billion by 2033 | Astute Analytica - GlobeNewswire Inc.
The Zacks Analyst Blog Salesforce, Shell and Gilead Sciences - Yahoo Finance
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences I - GuruFocus.com
Top Stock Reports for Salesforce, Shell, Gilead Sciences & Others - Yahoo Finance
Is Gilead Sciences (GILD) Among the Best NASDAQ Dividend Stocks to Buy? - Insider Monkey
Gilead settles with US government in long-running patent dust-up over PrEP meds Truvada, Descovy - FiercePharma
Gilead, US Settle Billion-Dollar Patent Feud Over HIV Drugs (1) - Bloomberg Law
Gilead's Kite taps longtime Amgen alum as new global commercial head - FiercePharma
JPM25 Day 3: AbbVie, Gilead, GSK and Dyne - BioSpace
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now? - Yahoo Finance
JPM Day 3: AbbVie, Gilead, GSK and Dyne - BioSpace
Rovin Capital UT ADV Trims Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
USA Financial Formulas Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Primary Sclerosing Cholangitis Market Deep Research Report Forecast by 2031 | Acorda Therapeutics, Inc., - EIN News
Gilead And US Settle HIV Drug Patent Dispute - Finimize
Assenagon Asset Management S.A. Lowers Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead, Feds Resolve HIV Drug Patent Dispute Amid Appeal - Law360
Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing - Yahoo Finance
Gilead reportedly settles CDC patent dispute over HIV drugs - Seeking Alpha
Gilead Sciences Inc. stock rises Wednesday, still underperforms market - MarketWatch
Biden administration and Gilead settle long-running battle over patents for HIV PrEP pills - STAT
Gilead Sciences, US government settle patent case over HIV prevention drugs - MSN
Autologous Cell Therapy Market Set to Witness Significant Growth by 2025-2032: Bristol Myers Squibb, Gilead - EIN News
40 Under 40: Rasika Iyer, Gilead Sciences - MM+M Online
April 17th Options Now Available For Gilead Sciences (GILD) - Nasdaq
Global Financial Private Client LLC Boosts Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Wright Investors Service Inc. Trims Stake in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences Inc. stock rises Monday, still underperforms market - MarketWatch
Gilead, LEO Pharma Partner in $1.7 Billion Deal for Inflammatory Disease Therapies - GuruFocus.com
LEO Pharma and Gilead Will Develop STAT6 Program for AD and Other Inflammatory Diseases - Dermatology Times
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):